| 1. |
|
|
| 2. |
- Håkansson, Bo, 1953, et al.
(författare)
-
A novel bone conduction implant (BCI): engineering aspects and pre-clinical studies.
- 2010
-
Ingår i: International journal of audiology. - : Informa UK Limited. - 1499-2027 .- 1708-8186. ; 49:3, s. 203-15
-
Tidskriftsartikel (refereegranskat)abstract
- Percutaneous bone anchored hearing aids (BAHA) are today an important rehabilitation alternative for patients suffering from conductive or mixed hearing loss. Despite their success they are associated with drawbacks such as skin infections, accidental or spontaneous loss of the bone implant, and patient refusal for treatment due to stigma. A novel bone conduction implant (BCI) system has been proposed as an alternative to the BAHA system because it leaves the skin intact. Such a BCI system has now been developed and the encapsulated transducer uses a non-screw attachment to a hollow recess of the lateral portion of the temporal bone. The aim of this study is to describe the basic engineering principals and some preclinical results obtained with the new BCI system. Laser Doppler vibrometer measurements on three cadaver heads show that the new BCI system produces 0-10 dB higher maximum output acceleration level at the ipsilateral promontory relative to conventional ear-level BAHA at speech frequencies. At the contralateral promontory the maximum output acceleration level was considerably lower for the BCI than for the BAHA.
|
|
| 3. |
- Marchand, M, et al.
(författare)
-
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2 : A clinical report
- 2003
-
Ingår i: European Journal of Cancer. - 0959-8049 .- 1879-0852. ; 39:1, s. 70-77
-
Tidskriftsartikel (refereegranskat)abstract
- Fifty-seven patients with MAGE-3-positive measurable metastatic cancer, most of them with melanoma, were vaccinated with escalating doses of a recombinant MAGE-3 protein combined with a fixed dose of the immunological adjuvant SBAS-2, which contained MPL and QS21. The immunisation schedule included 4 intramuscular (i.m.) injections at 3-week intervals. Patients whose tumour stabilised or regressed after 4 vaccinations received 2 additional vaccinations at 6-week intervals. The vaccine was generally well tolerated. Among the 33 melanoma patients who were evaluable for tumour response, we observed 2 partial responses, 2 mixed responses and 1 stabilisation. Time to progression in these 5 patients varied from 4 to 29 months. In addition, a partial response lasting 10 months was observed in 1 of the 3 metastatic bladder cancer patients included. None of the tumour responses described above involved visceral metastases. Immunological responses to the vaccine will be reported separately. ⌐ 2002 Elsevier Science Ltd. All rights reserved.
|
|
| 4. |
- Vagin, Mikhail, et al.
(författare)
-
Bioelectrocatalysis on Anodized Epitaxial Graphene and Conventional Graphitic Interfaces
- 2019
-
Ingår i: ChemElectroChem. - : WILEY-V C H VERLAG GMBH. - 2196-0216. ; 6:14, s. 3791-3796
-
Tidskriftsartikel (refereegranskat)abstract
- Graphitic materials exhibit significant anisotropy due to the difference in conductivity in a single layer and between adjacent layers. This anisotropy is manifested on epitaxial graphene (EG), which can be manipulated on the nanoscale in order to provide tailor-made properties. Insertion of defects into the EG lattice was utilized here for controllable surface modification with a model biocatalyst and the properties were quantified by both electrochemical and optical methods. A comparative evaluation of the electrode reaction kinetics on the enzyme-modified 2D material vs conventional carbon electrode materials revealed a significant enhancement of mediated bioelectrocatalysis at the nanoscale.
|
|
